A5030889403- Economic and Financial Impacts of Cancer
- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Cutaneous lymphoproliferative disorders research
- Sexual Differentiation and Disorders
- Male Reproductive Health Studies
- Cutaneous Melanoma Detection and Management
- Infectious Diseases and Mycology
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Women's cancer prevention and management
- Prostate Cancer Diagnosis and Treatment
AC Camargo Hospital
2021-2025
Eastern Cooperative Oncology Group
2024
Abstract Purpose Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments still challenging. This paper presents update expert panel consensus from Latin American Cooperative Oncology Group Cancer on advanced renal management in Brazil. Methods A 34 oncologists experts discussed voted best options for managing Brazil, including...
To evaluate the impact of assistance from public and private health systems on overall survival patients with metastatic prostate cancer. A total 213 cancer treated at A.C. Camargo Cancer Center, either in Unified Health System or a system, January 2014 to December 2018 were analyzed. Multivariate analysis was performed adjust for type other clinical prognostic factors. Of included patients, 147 (69%) system 66 (31%) System. There significant difference median age diagnosis between (63.4...
e17131 Background: QoL after radical prostatectomy (RP) may impact sexual functioning, with possible differences among age groups. Care management and ability to recognize risks favor the understanding of subjective well-being Value-based Healthcare (VBHC), measured through PROMs (patient reported outcome measures). Understanding changes between groups can raise evidence for better functionality promote rehabilitation approaches. Methods: Prospective, longitudinal, observational,...
Background: Tyrosine kinase inhibitors (TKI) and immunotherapy improved survival in metastatic renal cell carcinoma (mRCC). Disparities treatment access are present healthcare systems globally. The aim of this study was to analyze outcomes mRCC patients treated with first-line TKIs the public (PHS) private (PrS) health system a Brazilian Cancer Center. Materials Methods: Records from all 2007-2018 were reviewed retrospectively. Categorial variables compared by Fisher's exact test. Survival...
Several and important changes in the treatment of urological tumors occurred 2018.The studies with apalutamide (SPARTAN) enzalutamide (PROSPER) prior to development metastases benefited patients castration resistant prostate cancer.Prostate radiotherapy metastatic cancer improves overall survival (OS) men new diagnosed low disease burden per CHARTEED criteria.In another analysis this trial, abiraterone improve OS even low-risk de novo M1 castration-sensitive cancer.A phase III trial...